Fbxl18 targets LRRK2 for proteasomal degradation and attenuates cell toxicity

Xiaodong Ding1, Sandeep K Barodia2, Lisha Ma1

  • 1Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Neurobiology of Disease
|November 29, 2016
PubMed

Insights

Researchers discovered a new protein, Fbxl18, that regulates leucine-rich repeat kinase 2 (LRRK2) levels. This finding offers potential new therapeutic targets for Parkinson's disease (PD).

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Dominant LRRK2 mutations are a leading cause of familial Parkinson's disease (PD).
  • LRRK2 polymorphisms increase idiopathic PD risk, but mechanisms remain unclear.
  • Disease-linked LRRK2 mutations elevate kinase activity and cell toxicity.

Purpose of the Study:

  • To identify LRRK2-interacting proteins to understand LRRK2 function and PD pathogenesis.
  • To elucidate the role of novel interacting proteins in regulating LRRK2 levels and activity.

Main Methods:

  • Identification of LRRK2-interacting proteins using co-immunoprecipitation.
  • Characterization of Fbxl18 as a component of a Skp1-Cullin1-F-box ubiquitin ligase complex.
  • Assessment of Fbxl18's effect on LRRK2 ubiquitination, degradation, and cell toxicity.

Main Results:

  • Fbxl18 physically associates with LRRK2 and targets phosphorylated LRRK2 for degradation.
  • Fbxl18 knockdown increases LRRK2 abundance; protein kinase C activation enhances LRRK2 degradation.
  • Fbxl18 protects against cell death induced by wild-type and mutant LRRK2.

Conclusions:

  • Fbxl18 regulates LRRK2 protein levels through a ubiquitin-proteasome pathway.
  • Kinase signaling pathways modulate LRRK2 abundance via Fbxl18-mediated degradation.
  • Fbxl18 represents a potential therapeutic target for familial and idiopathic Parkinson's disease.